Lv41
590 积分 2024-02-15 加入
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
4小时前
已完结
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
4小时前
已完结
Silencing MUC1 to regulate intracellular lipid metabolism: Overcoming sunitinib resistance and inhibiting metastasis in renal cell carcinoma
16天前
已完结
Normative data for 144 compound remote associate problems
3个月前
已完结
Creativity: Yesterday, Today and Tomorrow
3个月前
已完结
Who is creative? Identifying children's creative abilities
3个月前
已完结
Can we trust creativity tests?
3个月前
已完结
Creativity
3个月前
已完结
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study
3个月前
已完结
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study
4个月前
已完结
皖公网安备34019202002308
